This article has been updated to correct the name and details of Personal Genome Diagnostics' test.
NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced today that its cancer testing contract with the US Department of Veterans Affairs has been amended to include its CancerSelect 125 test for pan-cancer tumor profiling.
In early 2015, the company signed an agreement to provide the VA with its CancerSelect cancer gene panel, which used next-generation sequencing to detect alterations in 88 cancer-associated genes, as part of a new precision oncology program (POP) at the agency. In late 2016, PGDx launched CancerSelect 125 — an expanded version of the panel covering 125 cancer genes that includes microsatellite instability testing.
PGDx said that CancerSelect 125 replaces CancerSelect in its deal with the VA, and will now be available to all cancer patients treated at VA centers nationwide. Additional terms of the deal were not disclosed.
"PGDx helped pioneer the VA's precision oncology program in 2015, and our involvement has grown as the POP has expanded from a regional lung cancer initiative into a nationwide effort covering all types of cancer," PGDx CEO Doug Ward said in a statement. "We welcome the opportunity to continue to provide our veterans battling cancer with the advanced, high-quality genomic testing that their service to our nation demands."